PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))))) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI). Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
Apple’s Upcoming iOS 17 Update: iPhone Users Must Prepare For A Significant Change
Apple has changed the position of the "End Call" button in the latest iOS 17 beta update, moving it to the lower right corner of the screen.
